Randomized, placebo-controlled Phase 2a study of SPL026 met its primary endpoint demonstrating a clinically significant reduction in depressive ...
The reduction in depression and anxiety symptoms 3 months after completing ten AMHSP sessions indicates a slow but meaningful benefit of the programme and supports the potential of a low-intensity, ...
The Rapid RCT Lab has worked with 16 departments across NYU Langone and completed 47 trials, and we are currently involved in ...
Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial Patients with advanced lung cancer reporting at least moderate ...
A digital pathology AI model to predict immune-oncology biomarker status and pembrolizumab response in a real-world cohort of patients with colorectal and breast cancer. Changes in non-small cell lung ...
The Rapid RCT Lab is a nationally-leading team conducting innovative, rapid RCTs to improve the delivery of services at the ...
‘A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial’ by David Erritzoe et al. was published in Nature Medicine at 16:00 UK time on ...
When a randomized evaluation finds null results, it is important to understand why. We investigated two very different explanations for the finding from a randomized evaluation that the Camden ...
Following the frequent suspicions regarding the safety of cholesterol-lowering drugs in the pre-statin era,1 statins have been a recurrent object of various concerns and alarming news. For example, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results